LONDON (Reuters) -Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback